

2023 Independent Medical Education Request for Proposal

Issue Date: April 14, 2023

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Request for Proposal (RFP) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech’s scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech RFPs are made available through our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this RFP will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on <http://funding.gene.com>)
2. This RFP does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this RFP.
4. For compliance reasons, and in fairness to all providers, all communications about this RFP must come exclusively to Genentech’s department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this RFP may result in a denial.

Instructions

Eligibility Criteria	<ul style="list-style-type: none"> ● U.S. based education provider ● Registered account in gFRS ● Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	<ul style="list-style-type: none"> ● Educational initiatives must be U.S.-based only

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this RFP will have 6 weeks to complete a full application. Please include "SMA RFP April 2023" in the title your program	May 26, 2023
Step 2	After 1 week, respective Genentech Medical Education Managers will review and provide notification of final decisions via email	June 2, 2023

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Currently Available RFP Focus Area:

Focus	Opportunity
<p>Therapeutic Area: Neuroscience</p> <p>Disease: Spinal Muscular Atrophy</p> <p>Learning Audience: Neurology Academic HCPs, Neurology Community HCPs, Primary Care Physicians, Adult Patients</p> <p>Support Available: Up to \$500,000</p> <p>Knowledge- and Competence-based Regional and Local Education <i>(Understanding & Addressing national or local gaps & emerging data)</i></p>	<p>Spinal muscular atrophy (SMA) is a neuromuscular disorder affecting both children and adults. The development of disease-modifying therapies within the past 5 years has moved disease management beyond purely supportive care approaches. It is important to help healthcare providers understand how to personalize therapeutic and supportive care plans for adult SMA patients.</p> <p>The transition of care from childhood to adulthood is an important consideration for individualizing treatment. There are many factors for a multidisciplinary team to consider beyond therapy alone, such as the physical, psychosocial, and logistical aspects of care for these adult SMA patients.</p> <p>Genentech would like to support independent medical education that addresses the current treatment landscape for adult SMA patients and the necessary considerations for the transition to adult care for SMA patients.</p> <p>References:</p> <ol style="list-style-type: none"> 1. Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal Muscular Atrophy. <i>Semin Pediatr Neurol.</i> 2021 Apr;37:100878. doi: 10.1016/j.spen.2021.100878. Epub 2021 Feb 11. PMID: 33892848. 2. Accogli G, Ferrante C, Fanizza I, Oliva MC, Gallo I, De Rinaldis M, Trabacca A. Neuromuscular disorders and transition from pediatric to adult care in a multidisciplinary perspective: a narrative review of the scientific evidence and current debate. <i>Acta Myol.</i> 2022 Dec 31;41(4):188-200. doi: 10.36185/2532-1900-083. PMID: 36793653; PMCID: PMC9896595.